This conference uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.
Micah leads the Strategy and Pipeline function within Allergan Aesthetics, which encompasses global commercial development/upstream marketing, external innovation, and research and analytics. Prior to his current role, he led AbbVie's enterprise innovation function, charged with supporting high-priority strategic issues across the organization. Micah joined AbbVie in 2019 after 7 years in the pharmaceuticals and medical products practice at consultancy McKinsey & Company.
Micah holds a Ph.D. in Cognitive Science from UCSD, was a Fulbright Fellow, and completed his undergraduate studies at Pomona College. His academic research on auditory perception and cognition is published in journals including PNAS and Current Biology.
Chris Chapman has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in January 2020, Mr. Chapman served in various roles at Galderma, most recently as Vice President and General Manager, U.S. Prescription Business. He previously served as the Senior Principal of the Core Access Group and as Executive Director for Managed Markets and Contracting for Medicis Pharmaceutical Corporation. He also served 20 years in commercial roles at Pfizer, where he led the U.S. Pharmaceutical Contracting and Pricing Organization. Mr. Chapman received his BS from Towson University.
Dr. Shimon Eckhouse is an inventor, active entrepreneur and investor in the field of medical devices and medical technology. Shimon founded Lumenis in 1992 and took it public on Nasdaq reaching a valuation of over $1B in the late nineties. Lumenis was founded by Shimon following his invention of IPL (Intense Pulsed Light) technology in 1992. This technology became one of the most popular and effective non-invasive treatment options for a broad range of aesthetic applications used by aesthetic doctors around the world.
After he left Lumenis in 1999 Shimon founded Syneron Medical in 2001 based on the novel concept of the use of combined light and bi-polar RF for non-invasive aesthetic treatments. Shimon took Syneron public on Nasdaq in 2004 and the company reached a valuation of over $1B. In 2010, Syneron acquired Candela lasers and became Syneron-Candela with Shimon serving as the Executive chairman of the company until it was sold to Apax partners in 2017. Both Lumenis and Syneron-Candela are world leaders in the field of energy-based devices used in aesthetic medicine with each of them reaching sales of over $350M.
Shimon is the co-founder of Sofwave and co-invented its revolutionary, FDA cleared, therapeutic ultrasound technology used for non-invasive skin tightening and serves as the executive chairman of the company. The company went public in the Tel-Aviv stock exchange in May 2021and successfully sells its products globally. Shimon is also co-founder of Hallura Medical that developed a revolutionary way of making cross linked Hyaluronic acid used for filler injections. The company is in advanced clinical trials in Europe which will be used for obtaining its CE mark regulatory clearance.
In 2015 Shimon founded a medical technology incubator in Israel-Alon Medtech Ventures that is starting companies in medical technology. Alon has grown leading medical technology companies and has an active portfolio of 16 companies five of them in the interventional cardiology field. Sofwave and Hallura were founded and have grown out of Alon Medtech.
Dr Eckhouse holds a BSc in physics from the Technion – Israeli Institute of Technology and a PhD in physics from the University of California at Irvine. He is an inventor and co-inventor of 63 US registered patents and many international patents. He published tens of scientific papers in leading refereed journals and conferences.
Mr. Fernandez is a Senior Managing Director and Senior Equity Research Analyst covering Global Biopharmaceutical and Biotechnology companies. Mr. Fernandez has more than 20 years of experience in the healthcare industry. Prior to joining Guggenheim, he was at LEERINK Partners, where he was a Managing Director and Senior Equity Research Analyst covering Pharmaceutical and Biotechnology companies. Previously, he was a Vice President at Cowen & Company. Mr. Fernandez earned his BA in Chemistry from Williams College in 1995.
Jonny Finlay is Scientific founder at Granular Therapeutics and CEO at LockBody Therapeutics (A Centessa Company); biologics drug discovery biotechs in the UK that are developing a series of therapeutics and technologies for inflammation and oncology indications. Jonny led research teams in Biologics Discovery and Development at Pfizer and Wyeth, and carried out postdoctoral research in recombinant protein engineering at several institutes, including the Centre for Biologics Evaluation and Research, FDA.
Jennifer Good is Trevi Therapeutics' co-founder and has served as a member of the board of directors and as the President and Chief Executive Officer since the Company's inception in March 2011. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company. Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. Ms. Good also currently serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, and is as the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Ms. Good is also one of the board members of the newly-formed Executive Women in Bio, CT Chapter. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.
Dr. Bhushan Hardas M.D., MBA is President of Jeune, Inc. Before joining Jeune, Dr. Hardas served as Chief Scientific Officer, Executive Vice President, Global Head of Licensing at Almirall and previously served as Chief Medical Officer of Allergan’s Dermatology and Medical Aesthetics business. Prior to joining Allergan, Dr. Hardas served as Senior Vice President, Global Head of Dermatology and Aesthetics R&D and Chief Scientific Officer of the North American Business at Merz Pharmaceuticals. Dr. Hardas received advanced training in clinical immunology and molecular biology at King’s College at the University of London, in London, England. He also completed a research fellowship in the Department of Dermatology at the University of Michigan, and received his Master of Business Administration degree in healthcare management from the University of California – Irvine.
Mr. Hartmann brings more than 25 years of leadership experience in growing new health technology markets. He has raised capital, grown and sold companies while successfully executing his roles in General Management, Sales, Marketing, Strategic and Business Development in the Medical Device Industry. Prior to Sofregen, Jonathan was CEO at Axsun Technologies, a leading developer and supplier of MEMS-based optical engines for medical imaging and industrial spectroscopy. Under Jonathan’s leadership, Axsun achieved significant milestones including the sales of over 15,000 lasers for OCT imaging applications in Cardiology and Ophthalmology. Mr. Hartmann led Axsun to successful acquisition by Excelitas, and serves on the Board of an Axsun spin-out, Nirrin Technologies, which is currently developing an enabling technology for Bio-Technology Processing and Manufacturing. Jonathan previously served as Axsun's GM and VP, then a subsidiary of Philips and Volcano Corporation. Prior to that, Jonathan spent 5 years at Volcano Corporation leading the Structural Heart and Forward Looking IVUS Business as GM and Business Unit Leader, and 6 years with Guidant Corporation until their acquisition by Boston Scientific.
Mr. Hartmann's background includes both small and large company experience ranging from product launches in laparoscopy with U.S. Surgical, to driving market development for smaller companies such as GI Dynamics where he served as V.P. of Sales and Marketing. He earned his B.S. at St. Lawrence University, and his MBA at Harvard Business School.
Mr. Hodder joined NFlection in October 2021 as Chief Executive Officer, bringing more than 35 years of broad biopharmaceutical industry experience including fundraising, business development, corporate and product marketing, sales, and product development.
Most recently, Mr. Hodder was Chief Business Officer for Escient Pharmaceuticals a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs for neuro-immuno-inflammatory and autoreactive diseases. Previously, he was Senior Vice President, Corporate Development at Protagonist Therapeutics (Nasdaq: PTGX), a clinical stage biotech company. Mr. Hodder also previously served as Vice President of Business Development and Corporate Officer at FibroGen, Inc., and Director of Business Development and Marketing at Aradigm, a drug delivery company. He has also held sales, marketing, and product development positions at Penederm (acquired by Mylan Laboratories), Ciba Geigy (now Novartis), Bristol-Myers Squibb Company, and Marion Laboratories (now Sanofi).
Mr. Hodder received a B.S. in biology from Oakland University and an M.B.A. from The University of Chicago Booth School of Business.
Dr. Kim is Co-Director for the Center for the Study of Itch and Sensory Disorders (CSISD) and Associate Professor of Medicine at Washington University School of Medicine in St. Louis. Key discoveries from his laboratory include the first identification of group 2 innate lymphoid cells (ILC2s) in the skin of both mice and humans and their role in the pathogenesis of atopic dermatitis (AD) or eczema. Most recently, he has discovered how the immune system directly regulates sensory neurons to modulate the sensation of itch and how natural killer (NK) cells may be used as an immunotherapy strategy for AD. These studies have revealed novel therapeutic strategies which have led to successful clinical trials for new drugs for AD. He has multiple patents pending that led to the formation of Nuogen Pharma, Inc. that is developing JAK inhibitors for chronic pruritus. Dr. Kim’s research on innate immunity and neuroimmune regulation of AD and itch has led to awards and funding from the National Institutes of Health, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, American Society for Clinical Investigation, American Dermatological Association, and the International League of Dermatology Societies.
Suma Krishnan is the founder and Chief Operating Officer at Krystal Biotech (NASDQ: KRYS) since 2016. She has over 25 years of drug development experience and has delivered on multiple gene therapy programs from discovery to the clinic as SVP and Head of Therapeutics at Intrexon Corporation (NYSE:XON). Previously, she led the discovery, development, and approval of Vyvanse (blockbuster drug to treat ADHD) as SVP, Product Development at New River Pharmaceuticals. Prior to that, Suma advanced approval of Adderall XR and Fosrenol at Shire. She began her career as a discovery scientist for Janssen Pharmaceuticals, Inc. Suma has over 20 publications and several issued patents. She received her Master of Science in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research, and an undergraduate degree in Organic Chemistry from Ferguson University.
Dr. Lee is a physician scientist with over 22 years in drug development. He joined Incyte in 2018 to lead the Inflammation and AutoImmunity (IAI) development group. His work at Incyte has allowed him to continue to apply his passion for science to develop innovative therapies for dermatological diseases. Prior to joining Incyte, Jim worked in clinical development and medical affairs at a number of dermatology focused biotech and pharmaceutical companies including GlaxoSmithKline, Graceway Pharmaceuticals and Dermavant Sciences. He has been involved in the development of many treatments for skin diseases, including imiquimod and ustekinumab; and now ruxolitinib cream. He is a member of the American Academy of Dermatology (AAD) and Society of Investigative Dermatology (SID).
Dr. Manstein is globally recognized for his leading role in the development of multiple dermatology breakthroughs, including fractional resurfacing (Fraxel®), cryolipolysis (Coolsculpting®), RF needle arrays (Profound®), and the IP behind R2 Dermatology and AVANA, Inc. He’s currently Assistant Professor of Dermatology at Harvard Medical School, in the Cutaneous Biology Research Center at Massachusetts General Hospital (MGH).
Dr. Mirza has held positions in pharmacovigilance at both Novartis and Shire, where he was a Medical Director supporting the Immunology and Oncology portfolios. He also has extensive experience as a medical monitor for pharmaceutical company’s and contract research organizations such as uniQure, Legend Biotech and Accelovance. Previously he worked across various companies as a consultant, with an area of focus in rare diseases and cell gene therapy.
Mansoor began his career in patient safety and vaccine research at Walter Reed Hospital, where he was involved in Streptococcus pneumonia vaccine development in adults and adolescents. He was also involved in a phase 1 clinical trial on a monovalent Ebola Zaire vaccine with the U.S. Department of Defense during his time at Accelovance as a lead medical monitor. His most recent medical monitoring responsibilities included support of two large COVID-19 investigational programs (an oral vaccine and a monoclonal antibody treatment for severe disease).
Gerry Muhle in his role as the head of the Global Business Unit for Aesthetics at Galderma, sets the overall strategy for the aesthetics business and is a core member of the inline and pipeline committees which cover all commercial matters and pipeline decisions globally. Gerry also currently chairs the R&D aesthetics steering committee working closely with the R&D and medical affairs organisations at Galderma. Gerry brings close to 30 years of experience in healthcare, with extensive international franchise experience as a senior leader for large marketing and cross-functional commercial businesses. Prior to joining Galderma Gerry was the Vice President & Head of International Strategic Marketing – Aesthetics at Allergan/AbbVie, delivering large-scale International digital transformation and consumer campaigns and leading many aesthetics launches across the world. Prior to this, Gerry held senior leadership roles in marketing and commercial strategy at Allergan and GlaxoSmithKline, including General Manager of Australia and New Zealand. He studied Science and, prior to working in pharmaceuticals, worked as a scientist primarily in the area of genetics with numerous publications to his name.
Gianfranco Nazzi is Chief Executive Officer of Almirall, S.A. since May 1, 2021 and Executive Director of its Board of Directors. He is also a member of the Board of EFPIA (European Federation of Pharmaceutical Industries and Associations).
Gianfranco joins Almirall from Teva Pharmaceuticals Industries Ltd, where he has most recently been serving as Executive Vice President of the International Markets Region and as a member of the Teva Executive Committee. While at Teva over the past seven years, he has held roles of increasing responsibility and geographic scope based in Israel and the Netherlands. He held the position of Senior Vice President Specialty Medicines Europe and President and CEO Growth Markets Region. Prior to Teva, Gianfranco held a variety of senior positions at Astra Zeneca, GSK and Eli Lilly in commercial and general management roles based in the UK, Italy, Serbia and the US.
Gianfranco is originally from Italy and holds a Degree in Economics and Banking Sciences from the University of Udine and a Master's Degree of Business Administration from the Bocconi University of Milan.
Dr. Piketty is a board-certified Dermatologist and Clinical Immunologist and has been Global Program Head at Galderma since 2018. He has extensive expertise in the development of topical compounds and systemic drugs, including biologics, from proof of concept to phase 3 in dermatology.
Dr. Mary Spellman is the Chief Medical Officer at Castle Creek Biosciences, Inc, a clinical-stage cell and gene therapy company. Dr. Spellman has broad clinical experience and has served as a clinical researcher and educator prior to her career as an industry-based biopharmaceutical and device developer. She has led Panclarity, LLC, providing executive level medical, safety and development services to life sciences companies, primarily supporting novel dermatology therapy and clinical development programs. Dr. Spellman is a diplomate of the American Board of Dermatology and a fellow of the American Academy of Dermatology.
Dr. Walker co-founded Aclaris Therapeutics, Inc. and has served as its President and CEO and a member of the board of directors since 2012. He is a board-certified dermatologist and serial entrepreneur with over 20 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson. Dr. Walker co-founded NeXeption LLC, a biopharmaceutical assets management company, in 2012. He co-founded and served as president and CEO and a member of the board of directors of Vicept Therapeutics Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics Inc., a specialty dermatology company, where he served as chief medical officer (acquired by Dr. Reddy's Laboratories Ltd.); and Cutix Inc., a commercial dermatology company. He also co-founded and continues to serve on the board of directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is on the board of directors of Aldeyra Therapeutics Inc., a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology. He received a Bachelor of Arts in biology from Lehigh University, a Master of Business Administration from The Wharton School, University of Pennsylvania, and a Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine.
Mr. Watanabe is the President, CEO and Director of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a late-stage dermatology biotech company. Mr. Watanabe has extensive experience across general management, marketing, sales management and business development in US, international and global markets. Under his leadership, Arcutis grew from 3 staff to more than 150, raised more than $600M in private and public financings, advanced multiple novel therapies from bench through the clinic, and filed its first New Drug Application with the FDA in Q3 2021. Prior to joining Arcutis, he was co-founder and Chief Operating Officer of Kanan Therapeutics, a cardiovascular drug development company, and before that, was Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals. Earlier in his career, he was an executive at Amgen, Inc., where he was involved in the development of Repatha® for hyperlipidemia and Aimovig® for migraine. Previously, he was an executive with Eli Lilly and company, and an official in the U.S. Government. He was also a commissioned officer in the U.S. Navy Reserves for 25 years. Mr. Watanabe earned his M.A. in National Security Studies, and his B.A. in International Relations, both at Georgetown University.
Todd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer and President of Aesthetics and Therapeutics at Revance. He served in global leadership roles at ZELTIQ Aesthetics prior to the company's acquisition by Allergan; at Galderma Laboratories, where he was President and General Manager of North America; and at Alcon Laboratories. He is a member of the board of directors of the Children's Skin Disease Foundation.
Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently the CEO and a director of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and immuno-oncology. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.
Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children's Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences.
William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.
Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Dr. Mark Lebwohl is Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai, and Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology at Mount Sinai. Dr. Lebwohl is past president of the American Academy of Dermatology and chairman emeritus of the Medical Board of the National Psoriasis Foundation. He is the founding editor of Psoriasis Forum and of the Journal of Psoriasis and Psoriatic Arthritis. He is editor of the Dermatology Section of Scientific American Medicine, and co-Editor-in-Chief of Skin, the Journal of Cutaneous Medicine. Dr. Lebwohl has chaired numerous symposia and has written, edited, or co-edited more than 20 books, authored or co-authored over 600 peer-reviewed publications and a similar number of invited articles and book chapters. Dr. Lebwohl played pivotal roles in the development of topical immunotherapy for the treatment of precancerous lesions known as actinic keratoses, in the development of topical calcineurin inhibitors for the treatment of psoriasis, in the development of numerous combination therapies for psoriasis including topical combination therapy, and in the introduction of numerous biologic therapies for psoriasis. He is actively involved in clinical trials of many new dermatologic treatments.
Ms. Seltzer is a Partner at Aisling Capital, a life sciences investment firm. She currently serves as a board member of Reneo Pharmaceuticals and as a board observer of Prolacta Bioscience. Her prior board positions include Agile Therapeutics, Aimmune Therapeutics (acquired by Nestle Health Sciences), AVROBIO, Durata Therapeutics (acquired by Actavis), Miramar Labs (acquired by Sientra), Promentis Pharmaceuticals, Spruce Biosciences, and ZELTIQ Aesthetics (acquired by Allergan).
Prior to Aisling, Ms. Seltzer worked at the pharmaceutical company Schering-Plough, where she held roles in business development, marketing and sales. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing innovative microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.
Ms. Seltzer serves on the Life Science Council for Springboard Enterprises and the Investment Advisory Board of the Blavatnik Fund for Innovation at Yale.
Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar, and her M.S. and B.S. in Molecular Biophysics and Biochemistry from Yale University, awarded cum laude.
Dr. Slaoui has served as Chief Corporate Development Officer at Galderma since September 2020. Previously she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. Since joining GSK’s Business Development teams in 2006, she has held various roles of increasing seniority and has executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009, participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.
Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship in Pharmacology at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.
Dr. Tang's research focuses on rare, monogenetic skin diseases such as Epidermolysis Bullosa (EB) and Basal Cell Nevus Syndrome (BCNS). Dr. Tang completed her MD/PhD at Stanford, post-doctoral fellowship with Dr. Ervin Epstein (UCSF), and has been at Stanford for the past 12 years. Dr. Tang was the PI of the investigator-initiated, Phase 1/2A clinical trial of autologous gene-therapy skin grafts for RDEB, and a co-founder of topical Patidegib (PellePharm) for BCC prevention in BCNS patients.
The networking lounge within the virtual meeting platform will be open to all attendees on the day of the event. Attendees can network via chat or video.
The current program agenda can be found here.
As an attendee you will be able to enjoy a unique, interactive experience from the comfort and convenience of your home or office. To make sure you are ready to go please review the following documents:
All companies who would like to sponsor the 2022 Virtual Dermatology Summit should provide a signed contract no later than December 17, 2021 in order to have a virtual presence. Branding and booth deliverables are required by the platform provider no later than December 18th in order to be included.
If you are interested in a sponsorship opportunity, please contact Amanda Pacia at email@example.com , for the sponsorship overview and level pricing.
Please check back for confirmed speaker deliverables or contact firstname.lastname@example.org
Requests for registration fee cancellations for the conference must be received on or before December 18, 2021. At the discretion of the conference organizers, a refund via the method of original payment, minus a $75 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on December 18, 2021. Written notice of your cancellation should be sent to email@example.com.
No damages or refunds shall be due for a failure of performance or because of a delay or cancellation of one or more of the AID Initiatives by the occurrence of any contingency beyond the reasonable control of Host. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, strikes, labor disputes, picketing or work stoppage (actual or threatened), an epidemic, pandemic or disease, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, change in virtual meeting platform ownership or management company, technology updates to the virtual meeting platform, interruptions or failure of the Internet, accessibility, connectivity or network connections, or any other acts beyond the reasonable control of the responsible parties.
Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.